PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The benefit of combining hyperthermia and chemotherapy to treat cancer is well established. However, combined
therapy has not yet achieved standard of care status. The reasons are numerous and varied, however the lack of
significantly greater tumor cell sensitivity to heat (as compared to normal cells) and the inability to deliver heat to the
tumor in a precise manner have been major factors. Iron oxide nanoparticle (IONP) hyperthermia, alone and combined
with other modalities, offers a new direction in hyperthermia cancer therapy via improved tumor targeting and an
improved therapeutic ratio. Our preliminary studies have demonstrated tumor cell cytotoxicity (in vitro and in vivo) with
IONP heat and cisplatinum (CDDP) doses lower than those necessary when using conventional heating techniques or
cisplatinum alone. Ongoing studies suggest such treatment could be further improved through the use of targeted
nanoparticles.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
A. A. Petryk, A. J. Giustini, P. Ryan, R. R. Strawbridge, P. J. Hoopes, "Iron oxide nanoparticle hyperthermia and chemotherapy cancer treatment," Proc. SPIE 7181, Energy-based Treatment of Tissue and Assessment V, 71810N (23 February 2009); https://doi.org/10.1117/12.810024